Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durlobactam/sulbactam - Entasis Therapeutics

Next Previous
Drug Profile

Durlobactam/sulbactam - Entasis Therapeutics

Alternative Names: beta-lactam/ETX-2514; ETX 2514/Sulbactam; ETX-2514SUL; SUL-DUR; Sulbactam-durlobactam; Sulbactam/durlobactam; SULBACTUM/ETX-2514; XACDURO; Xacduro

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Entasis Therapeutics; ZAI Lab
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Aza compounds; Carboxylic acids; Esters; Penicillins; Small molecules; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Nosocomial pneumonia; Ventilator associated pneumonia
  • Registered Acinetobacter infections
  • Phase II Pyelonephritis; Urinary tract infections
  • No development reported Burkholderia infections

Most Recent Events

  • 01 Apr 2025 Phase-I clinical trials in Acinetobacter infections (In adolescents, In adults, In children, In infants, In neonates) in USA (IV) (NCT06801223)
  • 01 Jan 2025 Launched for Nosocomial pneumonia (In adults) in China (IV)
  • 01 Jan 2025 Launched for Ventilator-associated-pneumonia (In adults) in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top